Search Results - "BARKER, J. N. W. N"

Validity of noninvasive markers of methotrexate-induced hepatotoxicity: a retrospective cohort study by Martyn-Simmons, C.L., Rosenberg, W.M.C., Cross, R., Wong, T., Smith, C.H., Barker, J.N.W.N.

“…Summary Background Methotrexate is a cost‐effective systemic treatment for moderate‐to‐severe psoriasis, but the perceived risk of associated liver fibrosis…”
Get full text

Psoriasis and its management by Smith, Catherine H, Barker, J N W N

“…Summary points Psoriasis is a common, disfiguring, and stigmatising skin disease associated with profound impaired quality of life The gene locus PSORS-1 is…”
Get full text

Demographics and disease characteristics of patients with psoriasis enrolled in the British Association of Dermatologists Biologic Interventions Register by Iskandar, I.Y.K., Ashcroft, D.M., Warren, R.B., Yiu, Z.Z.N., McElhone, K., Lunt, M., Barker, J.N.W.N., Burden, A.D., Ormerod, A.D., Reynolds, N.J., Smith, C.H., Griffiths, C.E.M.

“…Summary Background The British Association of Dermatologists Biologic Interventions Register (BADBIR) is a prospective, observational cohort designed to assess…”
Get full text

Antinuclear antibodies associate with loss of response to antitumour necrosis factor-α therapy in psoriasis: a retrospective, observational study by Pink, A.E., Fonia, A., Allen, M.H., Smith, C.H., Barker, J.N.W.N.

“…Summary Background  An increasing number of patients with severe psoriasis are failing to respond to antitumour necrosis factor (TNF)‐α therapy (etanercept,…”
Get full text

A classification of psoriasis vulgaris according to phenotype by Griffiths, C.E.M., Christophers, E., Barker, J.N.W.N., Chalmers, R.J.G., Chimenti, S., Krueger, G.G., Leonardi, C., Menter, A., Ortonne, J.-P., Fry, L.

“…Summary For nearly 200 years it has been appreciated that plaque psoriasis consists of a number of distinct clinical phenotypes. However, a reliable and simple…”
Get full text

A retrospective cohort study of the impact of biologic therapy initiation on medical resource use and costs in patients with moderate to severe psoriasis by Fonia, A., Jackson, K., LeReun, C., Grant, D.M., Barker, J.N.W.N., Smith, C.H.

“…Summary Background  Biologic therapy has become established as an important treatment option in patients with severe psoriasis, but is significantly more…”
Get full text

Identification of a novel psoriasis susceptibility locus at 1p and evidence of epistasis between PSORS1 and candidate loci by Veal, C D, Clough, R L, Barber, R C, Mason, S, Tillman, D, Ferry, B, Jones, A B, Ameen, M, Balendran, N, Powis, S H, Burden, A D, Barker, J N W N, Trembath, R C

“…The pathogenesis of all forms of psoriasis remains obscure. Segregation analysis and twin studies together with ethnic differences in disease frequency all…”
Get full text

Prioritizing the global research agenda in psoriasis: an International Psoriasis Council Delphi consensus exercise by Strober, B.E., Griffiths, C.E.M., O'Dell, S.J., Tebbey, P.W., Barker, J.N.W.N.

Get full text

Infliximab for the treatment of psoriasis in the U.K.: 9 years' experience of infusion reactions at a single centre by Wee, J.S., Petrof, G., Jackson, K., Barker, J.N.W.N., Smith, C.H.

“…Summary Background  Infliximab is an antitumour necrosis factor‐α chimeric monoclonal antibody that is an established treatment for severe chronic plaque…”
Get full text

Treatment of severe, recalcitrant, chronic plaque psoriasis with fumaric acid esters: a prospective study by Wain, E.M., Darling, M.I., Pleass, R.D., Barker, J.N.W.N., Smith, C.H.

“…Summary Background  Fumaric acid esters (FAE) are used in Germany as a first‐line systemic treatment for chronic plaque psoriasis, with proven efficacy and low…”
Get full text

Outcomes of methotrexate therapy for psoriasis and relationship to genetic polymorphisms by Warren, R.B., Smith, R.L., Campalani, E., Eyre, S., Smith, C.H., Barker, J.N.W.N., Worthington, J., Griffiths, C.E.M.

“…Summary Background  The use of methotrexate is limited by interindividual variability in response. Previous studies in patients with either rheumatoid…”
Get full text

British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005 by Smith, C.H., Anstey, A.V., Barker, J.N.W.N., Burden, A.D., Chalmers, R.J.G., Chandler, D., Finlay, A.Y., Grifitths, C.E.M., Jackson, K., McHugh, N.J., McKenna, K.E., Reynolds, N.J., Ormerod, A.D.

Get full text

A prospective case-controlled cohort study of endothelial function in patients with moderate to severe psoriasis by Martyn-Simmons, C.L., Ranawaka, R.R., Chowienczyk, P., Crook, M.A., Marber, M.S., Smith, C.H., Barker, J.N.W.N.

“…Summary Background  There is well‐documented evidence that patients with moderate and severe psoriasis have a significantly increased risk of cardiovascular…”
Get full text

Methotrexate polyglutamates as a marker of patient compliance and clinical response in psoriasis: a single-centre prospective study by Woolf, R.T., West, S.L., Arenas-Hernandez, M., Hare, N., Peters van Ton, A.M., Lewis, C.M., Marinaki, A.M., Barker, J.N.W.N, Smith, C.H.

“…Summary Background  Methotrexate is activated by the sequential addition of glutamic acid residues to form methotrexate polyglutamates (MTXPG1–5). MTXPG1–5…”
Get full text

Switching to adalimumab in patients with moderate to severe psoriasis who have failed on etanercept: a retrospective case cohort study by Woolf, R.T., Smith, C.H., Robertson, K., Barker, J.N.W.N.

Get full text

Polymorphisms in the PTPN22 region are associated with psoriasis of early onset by Smith, Rh.Ll, Warren, R.B., Eyre, S., Ke, X., Young, H.S., Allen, M., Strachan, D., McArdle, W., Gittins, M.P., Barker, J.N.W.N., Griffiths, C.E.M., Worthington, J.

“…Summary Background  Psoriasis, a chronic inflammatory skin disease, affects approximately 2% of the population worldwide. Although the aetiology of psoriasis…”
Get full text

The development of sarcoidosis on antitumour necrosis factor therapy: a paradox by Pink, A.E., Fonia, A., Smith, C.H., Barker, J.N.W.N.

Get full text

Screening for anxiety and depression in people with psoriasis: a cross‐sectional study in a tertiary referral setting by Lamb, R.C., Matcham, F., Turner, M.A., Rayner, L., Simpson, A., Hotopf, M., Barker, J.N.W.N., Jackson, K., Smith, C.H.

“…Summary Background National Institute for Health and Care Excellence guidance recommends assessment of psychological and social well‐being in people with…”
Get full text

Care of patients with psoriasis: an audit of U.K. services in secondary care by Eedy, D.J., Griffiths, C.E.M., Chalmers, R.J.G., Ormerod, A.D., Smith, C.H., Barker, J.N.W.N., Potter, J., Ingham, J., Lowe, D., Burge, S.

“…Summary Background  Medical professionals require data about the structure and delivery of dermatological services in primary and secondary care in order to…”
Get full text

Identification of a Major Susceptibility Locus on Chromosome 6p and Evidence for Further Disease Loci Revealed by a Two Stage Genome-Wide Search in Psoriasis by Trembath, Richard C., Lee Clough, R., Rosbotham, Jane L., Jones, Andrew B., Camp, Richard D. R., Frodsham, Angela, Browne, Julie, Barber, Ruth, Terwilliger, Joseph, Mark Lathrop, G., Barker, Jonathan N. W. N.

“…Psoriasis is a common chronic inflammatory disorder of the skin. To further understand the pathogenesis of psoriasis we have chosen to investigate the…”
Get full text